Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 9Prostatic Neoplasms 4Neoplasms 3Uveal Melanoma 2Stomach Neoplasms 1Renal Insufficiency, Chronic 1Oligodendroglioma 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Glioma 1Glioblastoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Bile Duct Neoplasms 1Astrocytoma 1

Interventions

Gemcitabine 40Cisplatin 24Capecitabine 21Fluorouracil 19Oxaliplatin 17Leucovorin 14pembrolizumab 9Irinotecan 8Radiotherapy 7Erlotinib Hydrochloride 7durvalumab 6Sorafenib 4Magnetic Resonance Spectroscopy 4Carboplatin 4trametinib 3Trastuzumab 3Photochemotherapy 3Long-Term Synaptic Depression 3Interleukin-12 Subunit p35 3Filgrastim 3Dihematoporphyrin Ether 3Dexamethasone 3Chemotherapy, Adjuvant 3trifluridine tipiracil drug combination 2tivozanib 2tislelizumab 2spartalizumab 2regorafenib 2olaparib 2dehydroftorafur 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Bile Duct Neoplasms × Protein Subunit Vaccines × Clear all
NCT00624182 2015-06-23

Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer

Akita University Hospital

Phase 1 Suspended
9 enrolled
Gastrointestinal

Bile Duct Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡